Nanomedicine for multimodality treatment of cancer

Nanomedicine

Volumn 7, Issue 12, 2012, Pages 1791-1794

  Mi, Yu ^a   Guo, Yajun ^b   Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

biodegradable polymer; biological therapy; chemotherapy; drug targeting; hyperthermia; nanoparticle

Indexed keywords

BEVACIZUMAB; CISPLATIN; COMBRETASTATIN A4; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLINIC ACID; INTERLEUKIN 2; LIPOSOME; NANOCARRIER; PACLITAXEL; PEMETREXED; PLACEBO; POLYCAPROLACTONE; POLYGLACTIN; SMALL INTERFERING RNA; TOCOFERSOLAN; TRASTUZUMAB;

ADVANCED CANCER; AREA UNDER THE CURVE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HYDROPHOBICITY; HYPERTHERMIC THERAPY; IC 50; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MICELLE; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NANOMEDICINE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTICLE SIZE; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR RECURRENCE; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NEOPLASMS;

EID: 84871343610     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.159     Document Type: Review

References (21)

1. Feng SS, Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci. 58, 4087-4114 (2003)
2. Feng SS, Mu L, Win KY, Huang GF. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 11, 413-424 (2004)
3. Feng SS. Chemotherapeutic engineering: concept, feasibility, safety and prospect - a tribute to Shu Chien's 80th birthday. Cell. Mol. Bioeng. 4, 708-716 (2011)
4. Mi Y, Liu YT, Guo YJ, Feng SS. Herceptin®- conjugated nanocarriers for targeted imaging and treatment of HER2-positive cancer. Nanomedicine (Lond.) 6, 311-312 (2011)
5. Zhao J, Mi Y, Liu YT, Feng SS. Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials 33, 1948-1958 (2012)
6. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636-2644 (2003)
7. Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23, 4265-4274 (2005)
8. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl. J. Med. 350, 2335-2342 (2004).
9. Westermann AM, Jones EL, Schem BC et al. First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer 104, 763-770 (2005).
10. Westermann A, Mella O, Van Der Zee J et al. Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an update. Int. J. Hyperther. 28, 549-553 (2012).
11. Colombo R, Da Pozzo LF, Salonia A et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol. 21, 4270-4276 (2003).
12. Mu L, Feng SS. Vitamin E TPGS used as emulsifier in the solvent evaporation/ extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol®). J. Control. Release 80, 129-144 (2002).
13. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26, 2713-2722 (2005).
14. Feng SS, Mei L, Anitha P, Gan CW, Zhou WY. Poly(lactide)-vitamin E derivative/ montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 30, 3297-3306 (2009).
15. Wang Y, Gao SJ, Ye WH, Yoon HS, Yang YY. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater. 5, 791-796 (2006).
16. Sengupta S, Eavarone D, Capila I et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436, 568-572 (2005).
17. Sun TM, Du JZ, Yao YD et al. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 5, 1483-1494 (2011).
18. Liu HY, Chen D, Li LL et al. Multifunctional gold nanoshells on silica nanorattles: a platform for the combination of photothermal therapy and chemotherapy with low systemic toxicity. Angew. Chem. Int. Edit. 50, 891-895 (2011).
19. Roy A, Singh MS, Upadhyay P, Bhaskar S. Combined chemo-immunotherapy as a prospective strategy to combat cancer: a nanoparticle based approach. Mol. Pharmaceut. 7, 1778-1788 (2010).
20. Peng CL, Lai PS, Lin FH, Wu SYH, Shieh MJ. Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles. Biomaterials 30, 3614-3625 (2009).
21. Mi Y, Liu X, Zhao J, Ding J, Feng SS. Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. Biomaterials 33, 7519-7529 (2012).